Overview

In particular, we provide the following essential services for the early-stage drug development process that many Korean companies focus on:

• Target Product Profile (TPP) definition
• Nonclinical and clinical development planning
• Individual nonclinical study and clinical trial design
• Support for establishing complex CMC (e.g., advanced biopharmaceuticals)
• Resolution of clinical pharmacology issues (e.g., effective dose determination, drug-drug interactions)
• Building integrated development evidence through pharmacometric approaches
• Development and execution of domestic and international regulatory strategies
• Scientific support during the out-licensing process
• Support for planning and conducting investigator-initiated clinical trials

We are also expanding collaborations with public institutions, overseas companies, and technology-focused businesses to deliver even greater value to our clients, and we are developing joint service offerings together with companies holding cutting-edge technologies.

We are grateful that more than 170 client companies have placed their trust in AIMS across over 320 projects, and these relationships remain active and ongoing. We value every partnership and take the greatest joy in helping our clients achieve maximum results with minimal time and cost.

Do you have concerns about new drug research and development? Is there something you need to prepare for? Please feel free to reach out with any questions — AIMS is the problem-solver for new drug development.